Elanco Animal Health, Basingstoke, UK.
Food and Drug Administration, Center for Veterinary Medicine, Rockville MD.
Microbiol Spectr. 2018 Jul;6(4). doi: 10.1128/microbiolspec.ARBA-0028-2017.
There is broad consensus internationally that surveillance of the levels of antimicrobial resistance (AMR) occurring in various systems underpins strategies to address the issue. The key reasons for surveillance of resistance are to determine (i) the size of the problem, (ii) whether resistance is increasing, (iii) whether previously unknown types of resistance are emerging, (iv) whether a particular type of resistance is spreading, and (v) whether a particular type of resistance is associated with a particular outbreak. The implications of acquiring and utilizing this information need to be considered in the design of a surveillance system. AMR surveillance provides a foundation for assessing the burden of AMR and for providing the necessary evidence for developing efficient and effective control and prevention strategies. The codevelopment of AMR surveillance programs in humans and animals is essential, but there remain several key elements that make data comparisons between AMR monitoring programs, and between regions, difficult. Currently, AMR surveillance relies on uncomplicated antimicrobial susceptibility methods. However, the lack of harmonization across programs and the limitation of genetic information of AMR remain the major drawbacks of these phenotypic methods. The future of AMR surveillance is moving toward genotypic detection, and molecular analysis methods are expected to yield a wealth of information. However, the expectation that these molecular techniques will surpass phenotypic susceptibility testing in routine diagnosis and monitoring of AMR remains a distant reality, and phenotypic testing remains necessary in the detection of emerging resistant bacteria, new resistance mechanisms, and trends of AMR.
国际上广泛认为,对各种系统中出现的抗菌素耐药性(AMR)水平进行监测是解决这一问题的策略的基础。监测耐药性的主要原因是确定(i)问题的规模,(ii)耐药性是否在增加,(iii)是否出现以前未知类型的耐药性,(iv)特定类型的耐药性是否在传播,以及 (v)特定类型的耐药性是否与特定的爆发有关。在设计监测系统时,需要考虑获取和利用这些信息的影响。AMR 监测为评估 AMR 的负担以及为制定高效和有效的控制和预防策略提供必要的证据提供了基础。人类和动物的 AMR 监测计划的共同发展是必不可少的,但仍有几个关键因素使得 AMR 监测计划之间以及各地区之间的数据比较变得困难。目前,AMR 监测依赖于简单的抗菌素敏感性方法。然而,各计划之间缺乏协调以及 AMR 的遗传信息有限仍然是这些表型方法的主要缺点。AMR 监测的未来正在向基因型检测发展,分子分析方法有望提供大量信息。然而,这些分子技术在常规诊断和监测 AMR 中的表现将超过表型药敏试验的预期仍然是遥远的现实,表型试验在检测新出现的耐药细菌、新的耐药机制和 AMR 趋势方面仍然是必要的。